Personalized Dietary Feedback to Reduce Hepatic Steatosis in Patients With MASLD (PERSOMA)
Effect of Personalized Dietary and Lifestyle Feedback on Hepatic Steatosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Prospective, Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) and combined metabolic dysfunction and alcohol-associated liver disease (MetALD) are common chronic liver diseases associated with metabolic dysfunction and an increased risk of liver-related and cardiovascular complications. Lifestyle modification, particularly dietary changes and increased physical activity, represents a cornerstone of treatment. However, general lifestyle recommendations are often insufficient to achieve sustained improvements.
This prospective, randomized controlled trial aims to investigate whether personalized dietary and lifestyle feedback based on a structured questionnaire is more effective in reducing hepatic steatosis than generic lifestyle recommendations.
A total of 174 patients with MASLD or MetALD will be randomized 1:1 to receive either personalized or generic written feedback at baseline and after 2, 4, and 6 months. Changes in hepatic steatosis, assessed by the controlled attenuation parameter (CAP), will be evaluated over a six-month period.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a prospective, single-center, randomized controlled trial designed to evaluate the effectiveness of personalized dietary and lifestyle feedback compared with generic recommendations in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction and alcohol-associated liver disease (MetALD).
A total of 174 adult patients with MASLD or MetALD will be randomized in a 1:1 ratio to an intervention group receiving individualized feedback based on a structured dietary and lifestyle questionnaire or a control group receiving standardized written recommendations.
Participants will complete the questionnaire at baseline and after 2, 4, and 6 months, followed by the corresponding written feedback. Clinical, anthropometric, laboratory, and non-invasive liver assessments, including vibration-controlled transient elastography (VCTE) and controlled attenuation parameter (CAP), will be performed at baseline and after six months.
The primary objective is to compare hepatic steatosis between the two groups after six months, adjusting for baseline CAP values. Secondary objectives include assessing changes in body weight, metabolic parameters, liver stiffness, dietary habits, physical activity, and health-related quality of life.
The study aims to determine whether a simple, scalable, personalized feedback approach can improve lifestyle management in patients with MASLD or MetALD.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Georg Semmler, MD PhD
- Número de teléfono: +4314040047410
- Correo electrónico: georg.semmler@meduniwien.ac.at
Ubicaciones de estudio
-
-
State of Vienna
-
Vienna, State of Vienna, Austria, 1090
- Medical University of Vienna
-
Contacto:
- Georg Semmler, MD PhD
- Número de teléfono: +4314040047410
- Correo electrónico: sld@meduniwien.ac.at
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 18-80 years.
- Controlled attenuation parameter (CAP) >248 dB/m.
- Sufficient German language proficiency to independently complete the questionnaires.
- Written informed consent to participate in the study.
Exclusion Criteria:
- Other active chronic liver disease.
- Significant alcohol consumption, defined as ≥50 g/day in women or ≥60 g/day in men.
- Pregnancy or breastfeeding.
- Type 1 diabetes mellitus.
- Initiation or dose modification of GLP-1 receptor agonists or other weight-modifying pharmacological therapies within the previous three months.
- Planned bariatric surgery during study participation.
- Severe or unstable medical condition that, in the investigator's judgment, may interfere with study participation or interpretation of study results.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Personalized Dietary Feedback
Participants will receive personalized written dietary feedback based on their individual responses to a structured questionnaire. The feedback will include tailored recommendations regarding dietary habits. Updated personalized feedback will be provided at baseline and after 2, 4, and 6 months. |
Participants receive individualized written dietary feedback based on their responses to a structured dietary questionnaire. The feedback includes an assessment of individual dietary habits, a visual representation of dietary patterns, and personalized recommendations to improve food choices and dietary quality. Updated feedback is provided at baseline and after 2, 4, and 6 months based on repeated questionnaire assessments. |
|
Comparador activo: Generic Dietary Feedback
Participants will receive standardized written dietary recommendations independent of their individual questionnaire responses. Generic feedback will be provided at baseline and after 2, 4, and 6 months. |
Participants receive standardized written dietary recommendations based on general nutritional guidelines. The information is identical for all participants in the control group and is not tailored to individual dietary habits or questionnaire responses. The same generic dietary information is provided at baseline and after 2, 4, and 6 months. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Hepatic Steatosis at 6 Months, Assessed by Controlled Attenuation Parameter (CAP) Using Vibration-Controlled Transient Elastography (VCTE)
Periodo de tiempo: 6 months (baseline CAP used for adjustment).
|
Hepatic steatosis will be quantified using the controlled attenuation parameter (CAP), measured in decibels per meter (dB/m) by vibration-controlled transient elastography (VCTE). The outcome measure is the CAP value at 6 months. The between-group difference at 6 months will be evaluated using analysis of covariance (ANCOVA), with baseline CAP included as a covariate. CAP is the only measurement reported for this outcome. |
6 months (baseline CAP used for adjustment).
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Body Weight from Baseline to 6 Months
Periodo de tiempo: Baseline and 6 months
|
Body weight will be measured in kilograms (kg). Change will be calculated as body weight at 6 months minus baseline body weight. |
Baseline and 6 months
|
|
Percentage Change in Body Weight from Baseline to 6 Months
Periodo de tiempo: Baseline and 6 months
|
Percentage change in body weight will be calculated as [(body weight at 6 months - baseline body weight) / baseline body weight] × 100. |
Baseline and 6 months
|
|
Change in Waist Circumference from Baseline to 6 Months
Periodo de tiempo: Baseline and 6 months
|
Waist circumference will be measured in centimeters (cm). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
|
Change in Hip Circumference from Baseline to 6 Months
Periodo de tiempo: Baseline and 6 months
|
Hip circumference will be measured in centimeters (cm). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
|
Change in Alanine Aminotransferase (ALT) from Baseline to 6 Months
Periodo de tiempo: Baseline and 6 months
|
Serum ALT will be measured in units per liter (U/L). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
|
Change in Aspartate Aminotransferase (AST) from Baseline to 6 Months
Periodo de tiempo: Baseline and 6 months
|
Serum AST will be measured in units per liter (U/L). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
|
Change in Gamma-Glutamyl Transferase (GGT) from Baseline to 6 Months
Periodo de tiempo: Baseline and 6 months
|
Serum GGT will be measured in units per liter (U/L). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Patient data can be shared upon reasonable request and after fulfilling all legal and data protection requirements from the EU.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .